Short answer
CALR and MPL testing looks for somatic driver mutations in myeloproliferative neoplasms, especially essential thrombocythemia and primary myelofibrosis. In practice these tests usually come after JAK2 testing or as part of a reflex panel when platelets stay high, the smear looks clonal, or the CBC still suggests an MPN after reactive causes have been considered. They are not general health-optimization tests, and they do not diagnose a blood cancer by themselves.
Where CALR and MPL fit
Mayo Clinic Laboratories describes an algorithmic reflex approach that starts with JAK2, then moves to CALR, then MPL if needed. CALR changes are usually exon 9 frameshifts, and MPL testing typically looks at exon 10. The goal is to separate a reactive platelet rise from a clonal myeloproliferative pattern when the CBC and smear still point that way.
| Gene/test | Why it may be ordered | What it cannot do alone |
|---|---|---|
| JAK2 | Often the first driver test in suspected MPNs with high platelets or high hematocrit. | Negative testing does not rule out every MPN. |
| CALR | Often considered after JAK2-negative ET or primary myelofibrosis workups. | Supports a clonal pattern, but it does not replace clinical diagnosis. |
| MPL | Can support selected ET or myelofibrosis diagnoses, especially in reflex panels. | May be absent even when an MPN is still considered. |
Why reactive causes come first
High platelets can be reactive from iron deficiency, inflammation, infection, surgery, bleeding, splenectomy, or other stressors. That is why clinicians often repeat the CBC, look for the trigger, and check whether the pattern is persistent before leaning on CALR or MPL. The mutation panel becomes more useful when the abnormality stays in place and the overall picture still suggests a clonal bone marrow disorder.
In a persistent thrombocytosis workup, a JAK2-first reflex path often makes more sense than jumping straight to broader testing. If the counts or smear remain suspicious after the obvious reactive causes are addressed, CALR and MPL help fill in the next step of the algorithm.
What a result means
A positive CALR or MPL result supports a clonal MPN in the right setting, most often essential thrombocythemia or primary myelofibrosis. It does not by itself decide urgency, thrombotic risk, or treatment. The exact mutation, the CBC trend, marrow findings, spleen size, symptoms, and any thrombosis history still matter.
CALR and MPL results are usually somatic findings acquired in blood-forming cells, not inherited family variants. That distinction matters because it changes how the result is used for the patient and whether relatives need targeted follow-up.
A negative result does not end the workup if the blood-count pattern still looks suspicious. It may mean the problem is reactive, that another driver such as JAK2 or BCR-ABL1 is more relevant, or that marrow review and broader testing are still needed.
Questions before acting
- Was JAK2 already done, and was it a V617F-only test or a broader panel?
- Are the platelets or hematocrit persistently abnormal, or did they rise during infection, bleeding, surgery, or iron deficiency?
- Does the smear show teardrop cells, leukoerythroblastosis, or other marrow-stress clues?
- Would marrow biopsy or hematology review still be needed if CALR and MPL are negative?
What the result still cannot prove
CALR or MPL results can support an MPN workup, but they do not by themselves replace marrow findings, blood-count patterns, or the need to consider reactive causes first.
FAQ
What are CALR and MPL testing used for?
They are used in the workup of myeloproliferative neoplasms, especially when essential thrombocythemia or myelofibrosis is suspected and JAK2 testing is negative or incomplete.
Why is JAK2 often checked before CALR or MPL?
JAK2 is a common first-line driver in suspected myeloproliferative neoplasms. If it is positive, the workup may already have a strong clonal clue; if it is negative, CALR and MPL can help fill in the next step.
Do CALR or MPL results diagnose cancer by themselves?
No. They support a diagnosis in the right clinical setting, but CBC trends, smear review, symptoms, spleen findings, and sometimes bone marrow evaluation still matter.
Can a negative CALR or MPL test rule out an MPN?
No. A negative result does not rule out all myeloproliferative neoplasms, and many workups also consider JAK2, CBC trend, EPO, iron studies, and marrow findings.
Are CALR and MPL mutations inherited?
Usually no. In the common MPN setting these are usually somatic mutations acquired in blood-forming cells rather than inherited family variants.
What should I ask before acting on the result?
Ask whether JAK2 was already done, whether the platelet or hematocrit pattern was persistent, whether reactive causes were considered, and whether hematology review or marrow testing is still needed.
Related guides: high platelet count interpretation, JAK2 testing for unexplained clots, BCR-ABL1 testing for CML, and CBC blood test.